Journal of Cardiac Failure
Volume 9, Issue 1 , Pages 36-41 , February 2003

Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure

Received 5 June 2002 ,Revised 31 October 2002

References 

  1. Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol. 2001;54:680–686
  2. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J. 1987;8(Suppl F):23–26
  3. Remme WJ. Overview of the relationship between ischemia and congestive heart failure. Clin Cardiol. 2000;23:IV4–IV8
  4. Kannel WB. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure. Cardiovasc Drugs Ther. 1997;11(Suppl 1):199–212
  5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  6. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249–254
  7. Sacks FM, Pfeffer MA, Moyer LA, Rouleau JL, Rutherford JD, Cole TG, et al  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1301–1307
  8. Segal R, Pitt B, Poole Wilson P, Sharma D, Bradstreet D, Ikeda LS, et al. Effects of HMG-COA reductase inhibitors (statins) in patients with heart failure (abstract). Eur J Heart Failure. 2000;2(Suppl 2):96
  9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–3023
  10. Executive Summary of the Third Report of The National Cholesterol Education Program NCEP . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  11. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al.  ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). American College of Cardiology Web site Available at http://www.acc.org/clinical/guidelines/failure/hf_index.htm2001;
  12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467
  13. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. Am J Cardiol. 1998;82:668–669
  14. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol. 1997;29:139–146
  15. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC, Alexander CM, Londhe A, et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303–1307
  16. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol. 2001;87:646–649
  17. Simpson RJ, Sueta CA, Boccuzzi SJ, Lulla A, Biggs D, Londhe A, et al.  Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction. Am J Cardiol. 1997;80(8B):53H–56H
  18. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al.  Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868–873
  19. Aronow WS, Han C. Frequency of congestive heart failure in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl treated with statins versus no lipid-lowering drugs. Am J Cardio. 2002;90:1497–1499
  20. Grundy SM, Coleman JI, Rifling BM, Keller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med. 1999;159:1670–1678
  21. Lai LL, Goblet M, Belo C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J. 2000;93:283–286
  22. Yarzebski J, Spencer F, Goldberg RJ, Lessard D, Gore JM. Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. Arch Intern Med. 2001;161:1521–1528
  23. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al.  Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458–1462

☆ Reprint requests: Carla A. Sueta, MD, PhD, Medical Review of North Carolina, 5625 Dillard Drive, Cary, NC 27511-9227.

☆☆ This analysis was funded by an unrestricted grant from Merck & Co., Inc. We wish to acknowledge and thank the many physicians and their staff who participated in the Merck-sponsored Quality Assurance Program.

PII: S1071-9164(02)25405-6

doi: 10.1054/jcaf.2003.5

Journal of Cardiac Failure
Volume 9, Issue 1 , Pages 36-41 , February 2003

Article Tools

* Image Usage & Resolution